Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp ccumulating evidence indicates that the sympathetic nervous system plays an important role in the pathogenesis of hypertension. 1-3 Activation of the sympathetic nervous system is involved in the stages, clinical forms, 24-h blood pressure patterns, end-organ damage, and metabolic abnormalities of hypertension. 1-3 Although peripheral factors are also involved, the central nervous system (CNS) mechanisms are considered crucial. 3-7 The results of recent studies strongly suggest that central sympathetic outflow is increased in hypertension. 3-7 Increased oxidative stress is also involved in the pathogenesis of hypertension. 8 Although there have been many studies regarding target organ damage in hypertension, relatively few studies have addressed the role of oxidative stress in sympathetic nervous system activation. 9-11 Based on the role of angiotensin II (Ang II) in the generation of reactive oxygen species (ROS), the relationship between brain angiotensin and central sympathetic outflow has been examined. 12,13 Our group was the first to report that increased ROS generation in the brainstem contributes to the neural mechanisms of hypertension in hypertensive rats, 14 and we and other investigators have reported additional evidence to support this concept and the potential therapeutic aspects. 9-11 This review focuses on the role of oxidative stress within the brain in the neural pathogenesis of hypertension.
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Increased Oxidative Stress in the Brain in Hypertension
Among the target organs of hypertensive vascular diseases, the brain is most affected by aging and oxidative stress. 15, 16 Cell membranes in the brain contain a high concentration of polyunsaturated fatty acids. These fatty acids are targeted by ROS, which elicit chain reactions of lipid peroxidation. Oxidative stress is determined by measuring levels of thiobarbituric acid-reactive substances (TBARS), end products of lipid peroxidation. The levels of TBARS reflect those of malondialedehyde, although the assay is not specific for malondialedehyde. 15, 17 There are some important points, however, for assessing the levels of TBARS. 17 The medium used for tissue preparation needs to contain a chelating agent and an antioxidant, and conditions for the assay must be kept constant. Therefore, we used another method for assessing the ROS production, which is electron spin resonance (ESR) spectroscopy. The amount of ROS was quantified by monitoring the time-dependent decay of the amplitude of the ESR spectra produced by the nitroxide radical 4-hydroxy-2,2,6,6-tetramethyl-piperidine-N-oxyl (hydroxyl-TEMPO) as a spin probe. 9, 14 The signal decay of ESR spectroscopy reflects oxidative stress more directly. Also, it has an advantage for in vivo study. 18 We evaluated oxidative stress in the brains of stroke-prone spontaneously hypertensive rats (SHRSP) compared with normotensive Wistar -Kyoto (WKY) rats. 9, 14 The rostral ventrolateral medulla (RVLM) is the major vasomotor center that determines basal sympathetic nervous system activity and it is essential for the maintenance of basal vasomotor tone. 3-7 Spontaneously hypertensive rats (SHR) or SHRSP exhibit increased sympathetic nervous system activity during the development of hypertension and are commonly used in experimental studies as models of human essential hypertension. 3- 7 We previously investigated whether ROS are increased in the RVLM of SHRSP. 14 First, we found that ROS levels measured by TBARS and ESR spectroscopy were increased in the RVLM of SHRSP compared with WKY HIROOKA Y et al.
rats. In addition, superoxide dismutase (SOD) expression and activity, which are ROS scavenging factors, were decreased in the RVLM of SHRSP compared with WKY rats. Functionally, microinjection of the membrane-permeable radical scavenger tempol into the RVLM decreased blood pressure, heart rate, and sympathetic nervous system activity in SHRSP but not in WKY rats. More importantly, overexpression of Mn-SOD, an antioxidant enzyme, in the RVLM of SHRSP decreased blood pressure and sympathetic nervous system activity. These findings strongly indicate that oxidative stress in the RVLM is increased in SHRSP and contributes to the neural mechanisms of hypertension. As described here, brain ROS is one of the results of generalized target organ damage, appearing earlier in the brain due to its susceptibility. The brain ROS would increase blood pressure via activation of the sympathetic nervous system and this would ultimately result in a vicious cycle. It would be possible, however, that brain ROS is involved in the early stage of hypertension in SHR or SHRSP, because we found that oxidative stress in the brain assessed on in vivo ESR was enhanced in young (6-week-old) SHR or SHRSP compared with age-matched WKY rats (unpublished data). The levels of TBARS were not different, probably because the levels of TBARS reflect lipid peroxidation caused by ROS. Other investigators also found that an increase in superoxide anions in the RVLM is associated with hypertension in SHR, 19 and reduced expression and activity in Cu/Zn-SOD and Mn-SOD within the RVLM contribute to oxidative stress and neurogenic hypertension in SHR. 20 An increase in oxidative stress within the RVLM also plays an important role in maintaining high arterial blood pressure and sympathetic activation in 2-kidney 1-clip (2K-1C) hypertensive rats, which is a renovascular hypertension model. 21 In that study, Oliveira-Sales et al demonstrated that the mRNA expression of NAD(P)H oxidase subunits (p47 phox and gp91 phox ) in the RVLM was greater in 2K-1C than in the control group. Interestingly, there were no differences in Cu/Zn-SOD expression between the two groups. TBARS levels in the RVLM were significantly greater in the 2K-1C than in the control group, suggesting enhanced oxidative stress. Functionally, microinjection of vitamin C into the RVLM decreased blood pressure and renal sympathetic nerve activity in 2K-1C but not in controls. Importantly, in a subsequent study, these authors suggested that the paraventricular nucleus of the hypothalamus is also involved. 22 Notably, although 2K-1C is a model of renovascular hypertension, suggesting that circulating Ang II is increased, angiotensin type I (AT1) receptor gene expression levels within the RVLM and paraventricular nucleus were upregulated in this model, indicating that ROS was produced via the activation of nicotinamide-adenine dinucleotide phosphate [NAD(P)H] oxidase.
Sources of ROS Production in the Brain
As a source of ROS production in the CNS, NAD(P)H oxidase is a major player. NAD(P)H oxidase is composed of two membrane-bound subunits, gp91 phox and p22 phox ; several cytoplasmic subunits, p47 phox , p40 phox , and p67 phox ; and the small G-protein Rac1. 23-26 Stimulation of AT1 receptors activates NAD(P)H oxidase by which the cytoplasmic subunits of Rac1NAD(P)H oxidase such as Rac1 bind to the membrane subunits, thereby activating the enzyme leading to superoxide generation. Rac1 requires lipid modification to migrate from the cytosol to the plasma membrane, which is a necessary step for activating ROS-generating NAD(P)H oxidase. NAD(P)H oxidase activity is greater in the brainstem of SHRSP than in that of WKY. 27, 28 We transfected adenovirus 
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encoding dominant-negative Rac1 into the RVLM of SHRSP and WKY rats (Figure 1) . 27 Rac1 activity in the RVLM tissue was increased in SHRSP compared to WKY rats (Figure 2) . 27 Importantly, we demonstrated that inhibition of Rac1-derived ROS in the RVLM decreased blood pressure, heart rate, and urinary norepinephrine excretion in SHRSP (Figure 3) . 27 A similar response occurs after inhibition of Rac1-derived ROS in the nucleus tractus solitarius (NTS). 28 In addition to the cytosolic production of ROS, mitochondria are the primary source of ROS production in many cells. Ang II increases mitochondrial ROS production in the RVLM, leading to sympathoexcitation. 29 Furthermore, NAD(P)H oxidase-derived ROS might trigger Ca 2+ accumulation, which leads to mitochondrial ROS production. 29 This suggestion is based on the finding that gene transfer of dominant negative Rac1 attenuated the Ang II-induced increase in reduced Mito-Tracker red fluorescence. 29 In contrast, impairment of mitochondrial electron transport chain complexes in the RVLM might be involved in the neural abnormality underlying hypertension in SHR. 30 This issue was recently discussed by Zimmerman and Zucker. 31 Although we did not detect impairment of brain mitochondrial respiratory complexes in SHRSP, we propose that mitochondria-derived ROS mediate sympathoexcitation via NAD(P)H oxidase activation. 29 Another possibility for ROS generation is uncoupling nitric oxide synthase (NOS). In the absence of l-arginine or with tetrahydrobiopterin, NO production from inducible NOS (iNOS) causes uncoupling from the oxidation of NADPH, resulting in superoxide generation. 9 iNOS overexpression in the RVLM causes hypertension and sympathoexcitation that is mediated by an increase in oxidative stress. 32 This might be relevant to our observation that iNOS expression levels in the RVLM are greater in SHRSP than in WKY rats. 33 In addition, microinjection of iNOS antagonists into the RVLM reduces blood pressure only in SHR, but not in WKY rats. 33 
ROS-Mediated Activation of Transcriptional Factors
It has been suggested that an Ang II-mediated influx of Ca 2+ in neurons depends on increased superoxide generation by a Rac1-dependent NAD(P)H oxidase. 34 Ang II also regulates neuronal activity via inhibition of the delayed rectifier potassium current. 35 Ang II-mediated upregulation of L-type Ca 2+ currents in neurons isolated from the NTS is inhibited by scavenging ROS, indicating a role for NAD(P)H oxidasederived superoxide in the activation of Ca 2+ channels in the NTS. 24 NAD(P)H oxidase-derived superoxide mediates an Ang II-induced pressor effect via the activation of p38 mitogenactivated protein kinase (MAPK) in the RVLM. 36 Recently, we suggested that AT1 receptor-activated caspase-3 acting through the Ras/p38 MAPK/extracellular signal-related protein kinase pathway in the RVLM is involved in sympathoexcitation in SHRSP. 37 These pathways may be downstream effectors of ROS in the RVLM, which in turn plays a crucial role in the pathogenesis of hypertension. Interestingly, the pro-apoptotic proteins Bax and Bad were enhanced and the anti-apoptotic protein Bcl-2 was decreased in the RVLM of SHRSP, and inhibition of caspase-3 normalized these changes in pro-and anti-apoptotic protein levels. 37 These alterations in the RVLM of SHRSP were stimulated by Ang II via activation of the AT1 receptors, which are upregulated in this strain and other hypertensive models. 38 It would be reasonable to consider that different mechanisms may be responsible for sympathoexcitation in different brain sites (influx of Ca 2+ for RVLM, apoptosis for NTS), and activation of the apoptotic pathway is involved in sympathoexcitation in the RVLM. 37 The exact physiologic implication of these observations requires further evaluation.
Effects of Angiotensin Receptor Blockers on Brain Oxidative Stress
The existence of an independent renin -angiotensin system in the brain is well established. Activation of the brain reninangiotensin system substantially contributes to the development and maintenance of hypertension through activation of the sympathetic nervous system, vasopressin release, and drinking behavior. 39, 40 There is considerable evidence that HIROOKA Y et al.
peripherally administered angiotensin receptor blockers (ARBs) penetrate the blood -brain barrier, although there are some differences among ARBs. 41,42 AT1 receptors are abundant in the circumventricular organs, such as the subfornical organ and the organum vasculosum lamina terminalis, and the area postrema, which lack a blood -brain barrier.
39-42
Therefore, peripherally administered ARBs can also bind to those areas, thereby inhibiting the central actions of Ang II. Oral treatment with the ARB telmisartan appears to inhibit the central responses to Ang II in awake rats. 43 Although other ARBs also inhibit the central actions of Ang II within the brain beyond the blood-brain barrier, 41,42,44 these effects might differ depending on the pharmacokinetics and properties of each drug (ie, lipophilicity etc). 43 We evaluated the 
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effect of treatment with telmisartan at either a high dose (10 mg · kg -1 · day -1 ) or a low dose (3 mg · kg -1 · day -1 ), or hydralazine for 30 days on hypertension. 45 Systolic blood pressure (SBP) and heart rate were measured using the tailcuff method. Urinary norepinephrine excretion was measured as a marker of the sympathetic nervous system activity. We evaluated ROS in the brain (cortex, cerebellum, hypothalamus, and brainstem) of SHRSP on ESR spectroscopy and TBARS. Oral treatment with telmisartan reduced SBP dosedependently and hydralazine reduced SBP to a similar level to the high dose of telmisartan (Figure 4) . Telmisartan reduced, while hydralazine increased, urinary norepinephrine excretion (Figure 4) . TBARS levels were significantly increased in each area of the brain of SHRSP compared with WKY rats (Figure 5 ). Oral treatment with telmisartan reduced the TBARS levels, but hydralazine did not ( Figure 5 ). These findings suggest that (1) anti-hypertensive treatment with telmisartan reduces ROS in the brain of SHRSP; (2) telmisartan decreases blood pressure, at least in part, via a reduction of the sympathetic nervous system activity in SHRSP; and (3) these effects induced by telmisartan might be associated with protection of the brain of SHRSP from oxidative stress. We also measured the concentration of hydroxyl radicals using a modified procedure based on the hydroxylation of sodium salicylate by hydroxyl radicals, 46 leading to the production of 2,3-dihydroxybenzoic acid (2,3-DHBA). 29, 47 Inhibition of Rac1 in the RVLM and oral treatment with telmisartan significantly decreased the production of hydroxyl radicals in the RVLM (Figure 6 ). 47 Recently, we used in vivo ESR to assess oxidative stress in the brain, and found that oral treatment with another ARB, olmesartan, reduces oxidative stress in the brain of SHRSP without inducing reflex activation of the sympathetic nervous system. 48 In that study we evaluated the in vivo ESR signal 
HIROOKA Y et al.
decay rates of the brain using methoxycarbonyl-PROXYL, a nitroxyl radical species, as a blood -brain barrier-permeable spin probe. 49 Oral treatment with olmesartan attenuated the exaggerated pressor response to an excitatory amino acid, l-glutamate, in the RVLM of SHR compared to WKY rats. 50 Further, the pressor response to microinjection of Ang II into the RVLM was diminished in SHR treated with olmesartan. 50 Thus, the importance of oxidative stress in the brain and hypertension is supported by our studies as well as those of others. 11 Several questions, however, remain to be answered. A recent study suggested that systemic administration of candesartan reduces brain Ang II levels because it attenuates the mRNA expression of both angiotensinogen and angiotensinconverting enzyme in Ang II-infused rats. 51 Whether systemic treatment with ARBs indirectly regulates brain Ang II remains to be determined. 52 
Effects of Other Cardiovascular Drugs on Brain Oxidative Stress
Considering that ARBs act to inhibit NAD(P)H oxidase activ- 
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ity, it is reasonable that ARBs have an antioxidant effect, although there are some unresolved questions, as mentioned previously. Calcium channel blockers, azelnidipine and amlodipine, but not nicardipine, which also have antioxidant properties, have a sympatho-inhibitory effect on the brain. 53, 54 In particular, treatment with azelnidipine reduces oxidative stress in the RVLM associated with a decrease in the activity of NAD(P)H oxidase, Cu/Zn-SOD, and Mn-SOD. 53 These effects might be related to an improvement in NO production, 55 because we also demonstrated that overexpression of endothelial NOS in the NTS or RVLM decreases blood pressure and heart rate via the inhibition of sympathetic nervous system activity. 56-59 Surprisingly, we also found that atorvastatin inhibits the sympathetic nervous system as a result of upregulating NO activity and reducing oxidative stress. [60] [61] [62] [63] Further studies are needed to determine if this mechanism is also applicable in humans.
Salt-Sensitive Hypertension and Brain Oxidative Stress
Activation of the sympathetic nervous system, in particular, an increase in central sympathetic outflow, plays an important role in the pathogenesis of salt-sensitive hypertension as well as that of kidney diseases. 64, 65 Recent studies suggest that oxidative stress in the brain contributes to blood pressure elevation in salt-sensitive hypertension. 66, 67 We demonstrated that high salt intake exacerbates blood pressure elevation and sympathetic nervous system activity during the development of hypertension in SHR, and these responses are mediated by increased ROS generation, probably because of an upregulation of AT1 receptors and NAD(P)H oxidase in the RVLM. 66 The findings of a recent study from Kyushu University Graduate School of Medical Sciences indicate that mice with pressure overload acquired brain salt-sensitivity. 68 This means that high salt intake increases the transport from the blood to the cerebrospinal fluid and the response of the sympathetic nerve activity to salt administered into the brain. These results suggest that pressure overload affects salt sensitivity, thereby enhancing central sympathetic outflow and cardiac function. 68 Left ventricular hypertrophy is an independent risk of cardiovascular event and high salt intake is an important environmental factor of hypertension, both of which increased ROS, and sympathoexcitation may be involved in the pathogenesis of the development of hypertension. A recent clinical trial suggested that left ventricular hypertrophy is related to cardiovascular events in Japanese high-risk hypertensive patients. 69 
Summary and Future Perspectives
Currently in Japan, many patients with hypertension also have metabolic syndrome. Importantly, the prevalence of metabolic syndrome increases linearly with an increase in heart rate among Japanese men and women, 70 suggesting that activation of the sympathetic nervous system is involved in the pathogenesis of hypertension. 71 The prevalence of obstructive sleep apnea has increased as a result of the increase in the number of obese patients with hypertension. Obese patients with sleep apnea have enhanced central sympathetic outflow, which worsens hypertension and leads to cardiovascular events. 72 Further, there is considerable evidence that psychological stress is a major risk factor for cardiovascular diseases and events associated with hypertension. 73 Another therapeutic target for the treatment of hypertension is heart failure with a preserved ejection fraction. 74 As suggested here, salt-sensitivity might also be enhanced in these patients, thereby further enhancing central sympathetic outflow. 68 Oxidative stress in the brain as well as other organs might underlie these mechanisms. Future studies of the effects of oxidative stress in the brain are warranted and will provide useful information for the treatment of hypertension.
